Targeting Beclin 1 in combination with necroptosis inducers, death ligands, or immunotherapy agents could provide a novel therapeutic axis to exploit in CRC and other apoptosis-resistant malignancies [25]. Here, BECN1 is linked to colorectal carcinoma.